51.75
price up icon1.02%   0.52
after-market 시간 외 거래: 51.75
loading
전일 마감가:
$51.23
열려 있는:
$48.91
하루 거래량:
244.52K
Relative Volume:
0.52
시가총액:
$3.54B
수익:
$38.34M
순이익/손실:
$-149.65M
주가수익비율:
-13.76
EPS:
-3.76
순현금흐름:
$-150.28M
1주 성능:
-0.33%
1개월 성능:
-0.06%
6개월 성능:
+7.01%
1년 성능:
+108.00%
1일 변동 폭
Value
$48.42
$51.95
1주일 범위
Value
$48.42
$52.39
52주 변동 폭
Value
$22.01
$61.61

Merus N V Stock (MRUS) Company Profile

Name
명칭
Merus N V
Name
전화
31 030 253 8800
Name
주소
YALELAAN 62, 3584 CM UTRECHT
Name
직원
229
Name
트위터
@MerusNV
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
MRUS's Discussions on Twitter

Merus N V Stock (MRUS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-11-02 개시 Canaccord Genuity Buy
2023-08-21 개시 TD Cowen Outperform
2022-08-02 개시 Stifel Buy
2022-02-11 개시 BMO Capital Markets Outperform
2022-02-10 개시 Needham Buy
2021-11-17 재개 Guggenheim Buy
2021-06-07 업그레이드 Citigroup Neutral → Buy
2021-04-08 개시 William Blair Outperform
2021-03-16 개시 SVB Leerink Outperform
2020-06-26 개시 H.C. Wainwright Buy
2020-05-27 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2019-11-20 재개 Guggenheim Buy
2019-06-28 개시 ROTH Capital Buy
2019-04-12 재개 Guggenheim Buy
2019-04-03 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2019-03-27 개시 Berenberg Buy
2018-01-02 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2017-09-15 개시 RBC Capital Mkts Outperform
2017-03-21 다운그레이드 Citigroup Buy → Neutral
2016-12-22 업그레이드 Citigroup Neutral → Buy
2016-11-07 다운그레이드 Citigroup Buy → Neutral
2016-06-13 개시 Citigroup Buy
2016-06-13 개시 Guggenheim Buy
2016-06-13 개시 Wedbush Outperform
모두보기

Merus N V 주식(MRUS)의 최신 뉴스

pulisher
04:36 AM

FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com UK

04:36 AM
pulisher
02:36 AM

Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat

02:36 AM
pulisher
01:18 AM

Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha

01:18 AM
pulisher
09:19 AM

US FDA extends review of Merus' gene-targeting cancer therapy - Reuters

09:19 AM
pulisher
08:24 AM

US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive

08:24 AM
pulisher
06:52 AM

Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha

06:52 AM
pulisher
06:47 AM

FDA extends review period for Merus's cancer drug Zeno - Investing.com

06:47 AM
pulisher
06:31 AM

Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire

06:31 AM
pulisher
05:42 AM

Harbor Capital Advisors Inc. Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat

05:42 AM
pulisher
Nov 04, 2024

abrdn plc Acquires Shares of 87,215 Merus (NASDAQ:MRUS) - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Merus sees cash runway into 2028 - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Merus reports Q3 EPS ($1.46), consensus (88c) - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.

Nov 02, 2024
pulisher
Nov 01, 2024

Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Merus N.V. Reports Q3 2024 Financial Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Merus falls after updated data for lung cancer therapy - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Oct 31, 2024
pulisher
Oct 27, 2024

Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat

Oct 27, 2024
pulisher
Oct 26, 2024

Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Moody Aldrich Partners LLC Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

Merus (NASDAQ:MRUS) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024
pulisher
Oct 23, 2024

(MRUS) Investment Report - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 21, 2024

nVerses Capital LLC Acquires 1,500 Shares of Merus (NASDAQ:MRUS) - Defense World

Oct 21, 2024
pulisher
Oct 17, 2024

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

Analysts Set Merus (NASDAQ:MRUS) Target Price at $82.00 - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Market Resilience: Merus N.V (MRUS) Finishes Weak at 51.35, Down -1.57 - The Dwinnex

Oct 16, 2024
pulisher
Oct 16, 2024

Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews

Oct 16, 2024
pulisher
Oct 15, 2024

A company insider recently sold 2,500 shares of Merus N.V [MRUS]. Should You also Consider to Sale? - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

A History of Outperforming Analyst Forecasts and Beating the Odds: Merus N.V (MRUS) - SETE News

Oct 15, 2024
pulisher
Oct 14, 2024

Merus (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Oct 14, 2024
pulisher
Oct 11, 2024

VP Controller, PAO Shuman Harry sale 2,500 shares of Merus N.V [MRUS] - Knox Daily

Oct 11, 2024
pulisher
Oct 10, 2024

Market Highlights: Merus N.V (MRUS) Ends on a Low Note at 52.09 - The Dwinnex

Oct 10, 2024
pulisher
Oct 10, 2024

There is no way Merus N.V (MRUS) can keep these numbers up - SETE News

Oct 10, 2024
pulisher
Oct 09, 2024

What is the investor’s view on Merus N.V (MRUS)? - US Post News

Oct 09, 2024
pulisher
Oct 08, 2024

Merus N.V (MRUS) receives a Buy rating from Truist - Knox Daily

Oct 08, 2024
pulisher
Oct 08, 2024

Merus (NASDAQ:MRUS) Holdings Lowered by The Manufacturers Life Insurance Company - Defense World

Oct 08, 2024
pulisher
Oct 07, 2024

Millennium Management LLC Has $14.39 Million Stock Position in Merus (NASDAQ:MRUS) - MarketBeat

Oct 07, 2024
pulisher
Oct 02, 2024

Prepare Yourself for Liftoff: Merus N.V (MRUS) - SETE News

Oct 02, 2024
pulisher
Oct 01, 2024

Guggenheim Raises Merus (NASDAQ:MRUS) Price Target to $111.00 - MarketBeat

Oct 01, 2024
pulisher
Oct 01, 2024

Checking in on Merus N.V (MRUS) after recent insiders movement - Knox Daily

Oct 01, 2024
pulisher
Oct 01, 2024

Merus (NASDAQ:MRUS) Price Target Raised to $111.00 at Guggenheim - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Merus NV: Driving Innovation in Cancer Treatment with Shares Valued at $50.33 - NasdaqNewsFeed

Oct 01, 2024
pulisher
Oct 01, 2024

Merus begins phase 3 trial for head and neck cancer therapy - Investing.com Canada

Oct 01, 2024
pulisher
Oct 01, 2024

Merus (NASDAQ:MRUS) Shares Up 4.7% - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Merus's SWOT analysis: bispecific antibody developer's stock shows promise - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

BMO maintains Merus $95 target on positive trial data By Investing.com - Investing.com Canada

Oct 01, 2024
pulisher
Sep 30, 2024

Merus begins phase 3 trial for head and neck cancer therapy By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Merus's SWOT analysis: bispecific antibody developer's stock shows promise By Investing.com - Investing.com Australia

Sep 30, 2024

Merus N V (MRUS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Merus N V 주식 (MRUS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Shuman Harry
VP Controller, PAO
Aug 20 '24
Sale
54.00
2,500
135,000
7,002
Silverman Peter B.
COO & GC
Jun 27 '24
Option Exercise
17.94
10,000
179,400
10,000
Silverman Peter B.
COO & GC
Jun 27 '24
Sale
60.00
10,000
600,000
0
Silverman Peter B.
COO & GC
Jun 17 '24
Option Exercise
24.36
62,000
1,510,280
62,000
Silverman Peter B.
COO & GC
Jun 17 '24
Sale
56.52
62,000
3,504,178
0
Shuman Harry
VP Controller, PAO
Jun 12 '24
Sale
57.84
7,300
422,232
7,002
Shuman Harry
VP Controller, PAO
Jun 10 '24
Sale
53.22
1,000
53,224
7,002
Shuman Harry
VP Controller, PAO
Jun 04 '24
Sale
52.89
6,000
317,354
7,002
Shuman Harry
VP Controller, PAO
Dec 19 '23
Sale
26.68
115
3,068
7,002
Silverman Peter B.
COO & GC
Dec 15 '23
Sale
25.00
22,386
559,650
0
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):